UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published i
November 01 2007 - 10:16AM
PR Newswire (US)
NEW YORK, Nov. 1 /PRNewswire-FirstCall/ -- Forest Laboratories,
Inc. (NYSE:FRX) today announced the results of a double-blind,
randomized, placebo-controlled clinical trial, published in the
November 2007 issue of the Journal of Clinical Hypertension, which
demonstrated that nebivolol significantly reduced sitting diastolic
and systolic blood pressure used as monotherapy among
African-American patients with stage I-II hypertension. The study
also found that nebivolol was well tolerated in comparison to
placebo, with a low incidence of traditional beta blocker side
effects, such as fatigue, sexual dysfunction, and depression. In
addition, nebivolol was not associated with adverse changes in
blood lipids and glucose levels. Nebivolol, a novel beta blocker,
is currently under review by the U.S. Food and Drug Administration
for the treatment of hypertension. African Americans have an
increased prevalence of high blood pressure, develop elevated blood
pressure earlier in life, and have higher rates of
hypertension-related death from stroke, heart disease, and
end-stage kidney disease. Although awareness of hypertension in
African Americans has increased in recent years, their control
rates (blood pressure
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2023 to Sep 2024